Ocular Findings and Blurring of Vision Associated with COVID-19 Virus during Pandemics in Iraq
Zainab Adel Hashim1, *, Suzan Kahatan M. Salih2, Marwan Younis Abdulla3
Identifiers and Pagination:Year: 2024
E-location ID: e18743641277380
Publisher ID: e18743641277380
Article History:Received Date: 15/08/2023
Revision Received Date: 17/11/2023
Acceptance Date: 28/11/2023
Electronic publication date: 02/02/2024
Collection year: 2024
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Coronavirus disease 2019 (COVID-19) emerged with a number of ophthalmologic manifestations. The most significant ocular symptoms included conjunctival discharge, redness, tears, itching, and a feeling of a foreign body in the eye.
To review and critically appraise ophthalmologic manifestations of COVID-19 in the form of rate and severity of visual impairment following ocular and systemic COVID-19 infections.
A cross-sectional study that was carried out at the outpatients’ clinic in Al-Diwaniyah Teaching Hospital from October 2020 to October 2022 were 135 patients seeking advice regarding their ocular complaints. They are PCR and /or CT-scan approved COVID-19 infection. Comprehensive eye examination done for these patients started with visual acuity assessment by Snellen chart, then refraction followed by examination of the eye and its adnexa by slit lamp for signs of inflammation.
The patients had a mean age of 47.5 years, and the rate of blurring of vision was 39.3%, whether they had ocular manifestation or not, and it showed substantial association with disease severity.
COVID-19 infection was associated with visual impairment, and the ophthalmologic manifestations severity was related to systemic morbidity.